Position in NVS
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$3,240,342
+$974,602 QoQ
Shares Held
20,676
+39.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#334
of 1,603 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Concurrent Investment Advisors, LLC holds $273,585,885 across 14 Drug Manufacturers - General names. NVS ranks #11 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
232,761 | $59,114,311 | |
| 2 | LLY |
ELI LILLY & Co
|
46,836 | $56,176,507 | |
| 3 | ABBV |
AbbVie Inc.
|
160,023 | $40,268,187 | |
| 4 | MRK |
Merck & Co., Inc.
|
280,871 | $36,091,923 | |
| 5 | PFE |
Pfizer Inc
|
891,770 | $21,473,821 | |
| 6 | AMGN |
Amgen Inc
|
51,650 | $18,703,497 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
266,252 | $15,341,440 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
81,664 | $10,317,429 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,240,342 | 20,676 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $2,265,740 | 14,833 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $2,042,543 | 14,815 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $1,391,147 | 10,848 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $1,290,329 | 10,663 | Shares | Sole | 2025-07-25 | |
| 2025-03-31 | $646,026 | 5,795 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $403,155 | 4,143 | Shares | Sole | 2025-02-03 | |
| 2024-09-30 | $429,484 | 3,734 | Shares | Sole | 2024-10-30 | |
| 2024-06-30 | $355,682 | 3,341 | Shares | Sole | 2024-07-30 | |
| 2024-03-31 | $292,511 | 3,024 | Shares | Sole | 2024-05-07 | |
| No filing history on record for this holder in this stock. | ||||||